Implantica Enhances RefluxStop™ Network in Germany
Implantica AG, a pioneering medtech company, is making significant strides in introducing advanced medical technology to treat acid reflux with their innovative RefluxStop™ device. With an overwhelming number of people suffering from gastroesophageal reflux disease (GERD), this new partnership opens doors to better treatment possibilities at notable medical institutions.
Strategic New Partnership for RefluxStop™
The renowned Universitätsklinik Magdeburg has recently commenced the RefluxStop™ procedure, marking a major milestone in this initiative. Surgeons Prof. Dr. med. Frank Benedix and Dr. med. Steffi Peglow had the privilege of conducting the first procedures with this device. The hospital, known for its extensive expertise in treating reflux conditions through over 25 specialized departments, signifies a critical advancement for patients in need of innovative solutions for their reflux issues.
Importance of INEK Collaboration
Universitätsklinik Magdeburg is an INEK reporting hospital, which plays a vital role in promoting the RefluxStop™ procedure towards potential reimbursement avenues in Germany. This breakthrough not only enhances treatment availability but also contributes to a growing network of INEK reporting centers now incorporating the RefluxStop™ system.
Expert Insights on RefluxStop™
Prof. Dr. Benedix expressed enthusiasm about offering patients the latest advances in surgical treatment for GERD, highlighting that the RefluxStop™ has already benefited hundreds of individuals across Germany and over a thousand in Europe. The positive long-term results and additional surgical options provided by RefluxStop™ are crucial for patients suffering from chronic reflux symptoms.
The Vision of Implantica’s Founder
Dr. Peter Forsell, the CEO and founder of Implantica, shared his vision for the RefluxStop™ initiative, emphasizing the wider implications of GERD on society. With an estimated 17% of the German populace facing this condition, the economic burden due to work absences linked to GERD is significant, costing an estimated €600 million annually. Forsell believes innovations like RefluxStop™ have the potential to transform patient outcomes and reduce overall healthcare expenses significantly.
About RefluxStop™
The RefluxStop™ device stands out in the market as a revolutionary treatment for acid reflux, differing from traditional surgical options by not placing pressure on the esophagus. Instead, it restores the lower esophageal sphincter to its natural position, allowing the body to manage reflux effectively without invasive encirclement.
This innovative approach focuses on reconstructing the three critical components of the anti-reflux barrier, which, when functionally impaired, can result in acid reflux. The RefluxStop™ aims to both restore and support the natural anatomy, enhancing the body's ability to address reflux challenges naturally.
Learn More About Implantica
Implantica is committed to transforming healthcare through advanced technology. With the RefluxStop™ already CE-marked for safety and efficacy, the company is further invested in creating accessible health solutions. Their diverse product pipeline features cutting-edge eHealth platforms designed to monitor vital health parameters and facilitate communication between patients and care providers remotely.
Frequently Asked Questions
What is the RefluxStop™ device?
The RefluxStop™ is a CE-marked implant designed to treat gastroesophageal reflux by restoring the natural function of the lower esophageal sphincter without traditional surgical pressures.
How does RefluxStop™ differ from traditional treatments?
Unlike traditional methods that encircle the food passageway, RefluxStop™ maintains the esophagus's natural anatomy, minimizing common side effects like swallowing difficulties.
Who are the key figures involved in the RefluxStop™ initiative?
Prof. Dr. med. Frank Benedix and Dr. med. Steffi Peglow are among the leading surgeons now performing RefluxStop™ procedures at the Universitätsklinik Magdeburg.
What impact does GERD have on the economy?
GERD significantly affects the economy, with estimated work absence costs exceeding €600 million a year, highlighting the need for effective treatments like RefluxStop™.
How does Implantica support patients using RefluxStop™?
Implantica aims to enhance patient outcomes through innovative treatments and ongoing support via their comprehensive eHealth platform, ensuring optimal care for GERD patients.
